Skip to main content
. 2021 Dec 7;11(12):1325. doi: 10.3390/jpm11121325

Figure 1.

Figure 1

Flowchart of the study population. LAMA, long-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid plus long-acting beta-2 agonist; COPD, chronic obstructive pulmonary disease; MPR, medical possession rate; LTRA, leukotriene receptor antagonist; ILD, interstitial lung disease.